Kuhnil Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin · Cardiovascular
These statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Phase 3 pipeline
- Atorvastatin Calcium 20mg, QD · Cardiovascular
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. - KI1001 · Ophthalmology
KI1001 is a regenerative medicine therapy designed to restore corneal endothelial cell function and transparency in corneal diseases. - KI1106 4g, QD · Oncology
KI1106 is a small molecule targeting the CD47/SIRPα axis. - KI1107 4 Capsules, QD · Diabetes
KI1107 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). - Omega-3 fatty acid ethylester90 · Cardiovascular
Omega-3 fatty acid ethylester reduces triglycerides and modulates lipid metabolism by increasing fatty acid oxidation and reducing hepatic triglyceride synthesis. - Rosuvastatin Calcium 20 MG, QD · Cardiovascular
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: